(Q78111218)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

title

Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

main subject

phase II clinical trial

1 reference

I Sekine

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

T Tamura

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

H Kunitoh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

K Kubota

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

T Shinkai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

Y Kamiya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

N Saijo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

page(s)

731-733

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

11 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

Challenges associated with evaluating the clinical utility of non-cytotoxic pharmaceutical agents in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

A call for change in anticancer drug evaluation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008303921033

7 January 2021

Identifiers

DOI

10.1023/A:1008303921033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10442198%20AND%20SRC:MED&resulttype=core&format=json

11 December 2019

1 reference